Hugel Aesthetics operates in the medical aesthetics sector, specialising in the production and distribution of botulinum toxins and dermal fillers. The company's approach combines Korean beauty innovation with manufacturing standards to develop its product portfolio, which includes the botulinum toxin product Letybo and the Saypha range of dermal fillers.
The company's technical capabilities span medical aesthetics manufacturing, with specific expertise in botulinum toxin production and dermal filler production. Its geographic footprint includes operations in South Korea and Austria, positioning it within both the Asian and European markets for aesthetic treatments.
Hugel Aesthetics frames its mission around making high-quality aesthetic treatments more accessible. The company describes a purpose-driven culture focused on empowering both practitioners and patients, with a stated aim of ensuring that aesthetic treatments are a source of confidence rather than compromise.
